Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Solnavägen 1, 17177, Stockholm, Sweden.
Department of Public Health and Primary Care, Ghent University, C. Heymanslaan 10, 9000, Ghent, Belgium.
Cardiovasc Diabetol. 2021 Feb 11;20(1):38. doi: 10.1186/s12933-021-01233-6.
Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data from two nationwide cohorts of patients suggested no gender difference as regards the risk for diabetes-related CV complications but indicated the presence of a gender disparity in risk factor management. The aim of this study was to investigate gender differences in screening for dysglycaemia, cardiovascular risk factor management and prognosis in dysglycemic CAD patients.
The study population (n = 16,259; 4077 women) included 7998 patients from the ESC-EORP EUROASPIRE IV (EAIV: 2012-2013, 79 centres in 24 countries) and 8261 patients from the ESC-EORP EUROASPIRE V (EAV: 2016-2017, 131 centres in 27 countries) cross-sectional surveys. In each centre, patients were investigated with standardised methods by centrally trained staff and those without known diabetes were offered an oral glucose tolerance test (OGTT). The first of CV death or hospitalisation for non-fatal myocardial infarction, stroke, heart failure or revascularization served as endpoint. Median follow-up time was 1.7 years. The association between gender and time to the occurrence of the endpoint was evaluated using Cox survival modelling, adjusting for age.
Known diabetes was more common among women (32.9%) than men (28.4%, p < 0.0001). OGTT (n = 8655) disclosed IGT in 17.2% of women vs. 15.1% of men (p = 0.004) and diabetes in 13.4% of women vs. 14.6% of men (p = 0.078). In both known diabetes and newly detected dysglycaemia groups, women were older, with higher proportions of hypertension, dyslipidaemia and obesity. HbA1c was higher in women with known diabetes. Recommended targets of physical activity, blood pressure and cholesterol were achieved by significantly lower proportions of women than men. Women with known diabetes had higher risk for the endpoint than men (age-adjusted HR 1.22; 95% CI 1.04-1.43).
Guideline-recommended risk factor control is poorer in dysglycemic women than men. This may contribute to the worse prognosis in CAD women with known diabetes.
在冠心病 (CAD) 患者中,血糖异常的管理存在性别差异,血糖异常定义为糖耐量受损 (IGT) 或 2 型糖尿病 (T2DM),这是一个医学挑战。最近来自两个全国性 CAD 患者队列的数据表明,糖尿病相关心血管并发症的风险无性别差异,但表明在危险因素管理方面存在性别差异。本研究旨在调查血糖异常、心血管危险因素管理和血糖异常 CAD 患者预后方面的性别差异。
研究人群(n=16259;4077 名女性)包括 ESC-EORP EUROASPIRE IV(EAIV:2012-2013,来自 24 个国家的 79 个中心)和 ESC-EORP EUROASPIRE V(EAV:2016-2017,来自 27 个国家的 131 个中心)的横断面调查中的 7998 名患者。在每个中心,由经过中心培训的工作人员采用标准化方法对患者进行调查,并且对无已知糖尿病的患者进行口服葡萄糖耐量试验 (OGTT)。主要终点为心血管死亡或非致命性心肌梗死、中风、心力衰竭或血运重建的首次住院。中位随访时间为 1.7 年。使用 Cox 生存模型评估性别与终点发生时间之间的关系,调整年龄因素。
已知糖尿病在女性中更为常见(32.9%),而在男性中则更为常见(28.4%,p<0.0001)。OGTT(n=8655)显示女性中 IGT 发生率为 17.2%,而男性为 15.1%(p=0.004),糖尿病发生率为 13.4%,而男性为 14.6%(p=0.078)。在已知糖尿病和新发现的血糖异常两组中,女性年龄更大,高血压、血脂异常和肥胖的比例更高。已知糖尿病女性的 HbA1c 更高。女性达到体力活动、血压和胆固醇推荐目标的比例明显低于男性。已知糖尿病女性的终点风险高于男性(年龄调整后的 HR 为 1.22;95%CI 为 1.04-1.43)。
血糖异常女性的指南推荐的危险因素控制较差。这可能导致已知糖尿病 CAD 女性的预后更差。